# Longitudinal plasma interleukin‐6 and post‐stroke cognitive outcomes: The Stroke‐IMPaCT study

**Authors:** Natasha S. Carmichael, Harry R. Deijnen, Siew Yan Wong, Thomas O. Williams, Evangelos Kontopantelis, Luke Cowie, Eileen Jones, Lauren Drag, Marion S. Buckwalter, John R. Grainger, Stuart M. Allan, Craig J. Smith

PMC · DOI: 10.1002/alz.71261 · 2026-03-10

## TL;DR

High levels of interleukin-6 in the months after a stroke are linked to worse long-term cognitive outcomes, suggesting a potential target for treatment.

## Contribution

This study identifies rising interleukin-6 levels as a stronger predictor of post-stroke cognitive decline than initial levels.

## Key findings

- A doubling of IL-6 between admission and 6–9 months was associated with cognitive impairment at 18–21 months.
- Smoking was linked to lower IL-6 levels and reduced Toll-like receptor signaling.
- Subacute IL-6 changes may help predict or guide interventions for cognitive outcomes after stroke.

## Abstract

Inflammatory factors, particularly interleukin (IL)‐6, are implicated in post‐stroke cognitive decline, yet the association with longitudinal changes in these markers remains unclear.

Plasma IL‐6 and other inflammatory markers were measured within 96 hours of ischemic stroke, and at 6–9 and 18–21 months, alongside cognitive assessment. Associations between inflammatory factors and cognition were examined using adjusted regression models.

A doubling of IL‐6 between admission and 6–9 months was associated with cognitive impairment at 18–21 months (odds ratio [OR] = 8.16; 95% confidence interval [CI] 1.82–47.26; p = 0.01), while each one‐unit IL‐6 increase was linked to a 1.5‐point decrease in memory Z‐scores (β = ‐1.50; 95% CI ‐2.57–0.43; p = 0.007). Smokers showed persistently blunted IL‐6 trajectories (p < 0.05) and downregulated Toll‐like receptor signaling (p < 0.05). Exploratory analyses suggested that lower socioeconomic status may relate to 6‐month IL‐6 concentrations via smoking.

Post‐stroke IL‐6 trajectories associate with later cognition, highlighting potential therapeutic targets.

Rising interleukin (IL)‐6 by 6–9 months post‐ischemic stroke relates to worse long‐term cognition.This association is stronger than that seen with admission IL‐6 levels.Exploratory analyses suggest smoking and higher deprivation may drive elevated IL‐6.Smoking reduces Toll‐like receptor (TLR) signaling, strengthening a link with post‐stroke IL‐6 levels.Subacute circulating IL‐6 changes may predict or enable interventions for cognition.

Rising interleukin (IL)‐6 by 6–9 months post‐ischemic stroke relates to worse long‐term cognition.

This association is stronger than that seen with admission IL‐6 levels.

Exploratory analyses suggest smoking and higher deprivation may drive elevated IL‐6.

Smoking reduces Toll‐like receptor (TLR) signaling, strengthening a link with post‐stroke IL‐6 levels.

Subacute circulating IL‐6 changes may predict or enable interventions for cognition.

## Linked entities

- **Proteins:** IL6 (interleukin 6)
- **Diseases:** ischemic stroke (MONDO:1060198)

## Full-text entities

- **Genes:** CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}
- **Diseases:** traumatic brain injury (MESH:D000070642), angina (MESH:D000787), hemorrhagic stroke (MESH:D000083302), neurological, psychiatric, or other condition (MESH:D001523), diabetes (MESH:D003920), ischemic (MESH:D002545), vascular disease (MESH:D014652), head injury (MESH:D006259), autoimmune neurological disease (MESH:D020274), acute coronary syndrome (MESH:D054058), Inflammatory (MESH:D007249), neurodegenerative disease (MESH:D019636), RESEARCH (MESH:D014947), nervous system infection (MESH:D009421), peripheral vascular disease (MESH:D016491), hyperlipidemia (MESH:D006949), blindness (MESH:D001766), intermittent claudication (MESH:D007383), Post-stroke (MESH:D020521), neuroischaemic ulceration (MESH:D014456), aphasia (MESH:D001037), renal artery stenosis (MESH:D012078), myocardial infarct (MESH:D009203), ischemic stroke (MESH:D002544), post (MESH:D000094025), ischemic injury (MESH:D017202), atrial fibrillation (MESH:D001281), ischemic brain injury (MESH:D001930), hypertension (MESH:D006973), left ventricular hypertrophy (MESH:D017379), smoker (MESH:C000719328), abdominal aortic aneurysm (MESH:D017544), Post-stroke cognitive decline (MESH:D003072), autoimmune, oncological or infectious disease (MESH:D003141), brain tumor (MESH:D001932), dementia (MESH:D003704), Coronary artery disease (MESH:D003324), TIA (MESH:D002546), infarct (MESH:D007238)
- **Chemicals:** nitrogen (MESH:D009584), EDTA (MESH:D004492), tocilizumab (MESH:C502936), water (MESH:D014867), ACK (-), alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12973141/full.md

---
Source: https://tomesphere.com/paper/PMC12973141